100 related articles for article (PubMed ID: 28169231)
1. Palbociclib: A new hope in the treatment of breast cancer.
Palanisamy RP
J Cancer Res Ther; 2016; 12(4):1220-1223. PubMed ID: 28169231
[TBL] [Abstract][Full Text] [Related]
2. Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?
Roncato R; Puglisi F; Gerratana L
Breast Cancer Res Treat; 2024 Jan; 203(1):183-184. PubMed ID: 37804389
[No Abstract] [Full Text] [Related]
3. Progress with palbociclib in breast cancer: latest evidence and clinical considerations.
Rocca A; Schirone A; Maltoni R; Bravaccini S; Cecconetto L; Farolfi A; Bronte G; Andreis D
Ther Adv Med Oncol; 2017 Feb; 9(2):83-105. PubMed ID: 28203301
[TBL] [Abstract][Full Text] [Related]
4. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Kim ES; Scott LJ
Target Oncol; 2017 Jun; 12(3):373-383. PubMed ID: 28488183
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.
Ettl J; Harbeck N
Expert Rev Anticancer Ther; 2017 Aug; 17(8):661-668. PubMed ID: 28649895
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 inhibitors in HER2-positive breast cancer.
Corona SP; Ravelli A; Cretella D; Cappelletti MR; Zanotti L; Dester M; Gobbi A; Petronini PG; Generali D
Crit Rev Oncol Hematol; 2017 Apr; 112():208-214. PubMed ID: 28325261
[TBL] [Abstract][Full Text] [Related]
7. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Ma CX; Gao F; Luo J; Northfelt DW; Goetz M; Forero A; Hoog J; Naughton M; Ademuyiwa F; Suresh R; Anderson KS; Margenthaler J; Aft R; Hobday T; Moynihan T; Gillanders W; Cyr A; Eberlein TJ; Hieken T; Krontiras H; Guo Z; Lee MV; Spies NC; Skidmore ZL; Griffith OL; Griffith M; Thomas S; Bumb C; Vij K; Bartlett CH; Koehler M; Al-Kateb H; Sanati S; Ellis MJ
Clin Cancer Res; 2017 Aug; 23(15):4055-4065. PubMed ID: 28270497
[No Abstract] [Full Text] [Related]
8. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Raphael J; Helou J; Pritchard KI; Naimark DM
Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer.
Mamiya H; Tahara RK; Tolaney SM; Choudhry NK; Najafzadeh M
Ann Oncol; 2017 Aug; 28(8):1825-1831. PubMed ID: 28472324
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker SR; Mallinger A; Workman P; Clarke PA
Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
[TBL] [Abstract][Full Text] [Related]
12. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Sammons SL; Topping DL; Blackwell KL
Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Matter-Walstra K; Schwenkglenks M; Dedes KJ
Breast Cancer Res Treat; 2017 Jun; 163(3):635. PubMed ID: 28321586
[No Abstract] [Full Text] [Related]
14. Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer.
Li N; Du EX; Chu L; Peeples M; Xie J; Barghout V; Tang DH
Expert Opin Pharmacother; 2017 Aug; 18(12):1167-1178. PubMed ID: 28699804
[TBL] [Abstract][Full Text] [Related]
15. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
Tripathy D; Bardia A; Sellers WR
Clin Cancer Res; 2017 Jul; 23(13):3251-3262. PubMed ID: 28351928
[TBL] [Abstract][Full Text] [Related]
17. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Chirila C; Mitra D; Colosia A; Ling C; Odom D; Iyer S; Kaye JA
Curr Med Res Opin; 2017 Aug; 33(8):1457-1466. PubMed ID: 28463012
[TBL] [Abstract][Full Text] [Related]
18. PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients.
Iwata H; Im SA; Masuda N; Im YH; Inoue K; Rai Y; Nakamura R; Kim JH; Hoffman JT; Zhang K; Giorgetti C; Iyer S; Schnell PT; Bartlett CH; Ro J
J Glob Oncol; 2017 Aug; 3(4):289-303. PubMed ID: 28831437
[TBL] [Abstract][Full Text] [Related]
19. Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence.
Polk A; Kolmos IL; Kümler I; Nielsen DL
ESMO Open; 2016; 1(6):e000093. PubMed ID: 28848657
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
